GSK GSK plc: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization

GSK plc (GSK) production relies on automated lines and AI modeling. The Enterprise Value to EBITDA multiple reflects the market valuation trend, while 9.19 captures the current state of this parameter. Following the asset spin-off, the holding is aggressively developing R&D in oncology and RSV vaccines, expanding access to HIV therapy and prevention for the elderly across global markets.

GlaxoSmithKline - GSK Enterprise Value to Operating Income Before Depreciation (period 11/23/2025 - 11/10/2026)

gsk.com - analytical breakdowns and key metrics (GSK)

- market price and analyst price targets:

Price Chart GlaxoSmithKline|GSK - Average Forecast Price

- company stock capitalization data:

Market Value GSK Corp|GSK - Total Company Value

- book value of equity indicators:

Book Value per Share GSK|GSK - Accounting Capitalization|Market Capitalization to Book Value Ratio gsk.com|GSK - Company Total Asset Base

- business debt structure and liquidity details:

- financial results and valuation multiples details:

GSK - Net Profit|Future Profit GSK plc|GSK - Company Value to Net Income|Future Price to Earnings GlaxoSmithKline|GSK - Market Cap to Earnings and Growth Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization GSK Corp|GSK - Profit before payment of interest, taxes and amortization|Net earnings per share (EPS TTM) GSK|GSK - Net earnings per share for the last 12 months|Quarterly EPS earnings growth gsk.com|GSK - Net earnings per share change in current year|Net earnings per share growth forecast for next year GSK plc

Basic company analysis:GSK Corp GSK

EV/EBITDA measures the total value of a business relative to its earnings before interest and taxes, neutralizing the impact of capital structure. Investors utilize this multiple to identify overvalued assets and protect portfolios from inflated expectations. By analyzing the historical EV/EBITDA trend of a company, one can assess the market value of R&D investments. The high valuation of GSK plc (GSK) is driven by strategic funding of innovation centers and partnerships with universities.

Main competitors

Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Eli Lilly & Co. LLY|AbbVie Corp. (ABBV) - Company Value to EBITDA|AZN - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|NVS: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|MRK: EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation NVO|AMGN (Amgen Corporation) - EV/EBITDA Multiple|Pfizer Corp (PFE) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Sanofi (SNY)|bms.com - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple TAK (Takeda)|Enterprise Value to EBITDA Multiple Teva Pharma|Dr. Reddy's Lab - EV/EBITDA Multiple|Enterprise Value to EBITDA Multiple Mylan (VTRS)|Roivant Sciences Ltd. (ROIV) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|ZLAB - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Bausch Health|EV/EBITDA Multiple Cosmos Health, Inc.